Form 8-K - Current report:
SEC Accession No. 0001213900-25-048998
Filing Date
2025-05-29
Accepted
2025-05-29 17:10:34
Documents
14
Period of Report
2025-05-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0243837-8k_cero.htm   iXBRL 8-K 45845
2 THIRD AMENDMENT TO THE CERO THERAPEUTICS HOLDINGS, INC. 2024 EQUITY INCENTIVE PL ea024383701ex10-1_cero.htm EX-10.1 8131
  Complete submission text file 0001213900-25-048998.txt   270381

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE cero-20250529.xsd EX-101.SCH 3797
4 XBRL DEFINITION FILE cero-20250529_def.xml EX-101.DEF 26672
5 XBRL LABEL FILE cero-20250529_lab.xml EX-101.LAB 36816
6 XBRL PRESENTATION FILE cero-20250529_pre.xml EX-101.PRE 25296
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0243837-8k_cero_htm.xml XML 5778
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 251004654
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)